Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Procedures mentioned: Blood draws
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "At each evaluation time point, participants will have a blood draw performed."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study collects health data from adults with invasive lobular breast cancer that has spread to distant parts of the body. This cancer starts in the breast’s milk-making glands. The data will help develop a tool to measure how this type of cancer responds to treatment.
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- A tissue test confirms invasive lobular breast cancer. Cancer with both lobular and ductal types is allowed.
- Age 18 or older.
- Any receptor type is allowed, meaning any hormone receptor or HER2 status.
- Able to understand the written consent form and willing to sign it.
Who can't join
- Stage I, II, or III breast cancer.
- The tumor tissue test does not show lobular cancer.
- Another active cancer. Past cancer is allowed if it was treated and there are no current signs of it.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: 1. Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed. 2. Age \>=18 years 3. Any receptor subtype. 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Stage I-III breast cancer. 2. Lack of lobular histology on tumor biopsy. 3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).
Study sites (4)
CA
- University of California, San Diego · San Diego, CA 92053Rebecca Shatsky, MD · Principal investigatorMore trials in San Diego
- University of California, San Francisco · San Francisco, CA 94122Venezia Garza · Study contact · 415-353-8732 · venezia.garza@ucsf.eduRita Mukhtar, MD · Principal investigatorA. Jo Chien, MD · Principal investigatorMore trials in San Francisco
PA
- Abramson Cancer Center · Philadelphia, PA 19104Rachel Jankowitz, MD · Principal investigatorMore trials in Philadelphia
TX
- MD Anderson Cancer Center · Houston, TX 77030Jason Mouabbi, MD · Principal investigatorMore trials in Houston